Taysha Gene Therapies Long Term Debt 2020-2024 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
Dr Reddy's Laboratories (RDY)	$13.1B
BridgeBio Pharma (BBIO)	$5B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M